15h

GSK is writing one of its biggest checks in years. The British drugmaker announced today it has agreed to acquire Boston-based cancer specialist Nuvalent in an all-cash deal worth $10.6 billion, securing three lung cancer therapies and a foothold in a competitive but lucrative corner of oncology dominated by Roche and Pfizer. The deal positions […] The post Nuvalent buyout: what it means for lung cancer patients appeared first on Rolling Out .